Key clinical point: Treatment with macitentan and tadalafil can elicit improvements in patients with newly diagnosed pulmonary arterial hypertension.
Major finding: There was a significant 47% reduction in pulmonary vascular resistance from baseline to week 16.
Study details: Phase 4 study of 46 patients.
Disclosures: Actelion Pharmaceuticals funded the trial. Dr. Sitbon disclosed relationships with Actelion, Bayer, GSK, Merck, Arena Pharmaceuticals, Gossamer Bio, and Ferrer.
Sitbon O et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.825.